Variable | Whole cohort (n=89) | Early aPHT (n=62) | ||
Positive responder (n=41) | Non-Responder (n=48) | Positive responder (n=38) | Non-responder (n=24) | |
Overall outcome | ||||
Survival-free of disability at 18 months† | 19/37 (51%) | 7/48 (15%)* | 18/34 (53%) | 7/24 (29%) |
Neonatal outcomes | ||||
Predischarge mortality | 14/41 (34%) | 34/48 (71%)* | 13/38 (34%) | 14/24 (58%)*** |
Mortality early (<7 days after iNO exposure) | 9/41 (22%) | 28/48 (58%)* | 8/38 (21%) | 11/24 (46%)** |
Late mortality (≥7 days after iNO exposure) | 5/41 (12%) | 6/48 (13%) | 5/38 (14%) | 3/24 (13%) |
≥ Grade 3 intraventricular haemorrhage | 5/41 (12%) | 7/48 (15%) | 2/38 (5%) | 1/24 (4%) |
Chronic lung disease‡ | 15/27 (56%) | 10/14 (71%) | 13/25 (52%) | 7/10 (70%) |
Any morbidity during hospital stay‡§ | 16/27 (59%) | 13/14 (93%)** | 14/25 (56%) | 9/10 (90%) |
Duration of invasive ventilation (days)‡ | 7 (4, 13) | 9 (5, 36) | 6 (4, 12) | 8 (5, 11) |
Duration of non-invasive ventilation (days)‡ | 32 (5, 51) | 30 (14, 59) | 32 (6, 52) | 31 (11, 59) |
Length of hospital stay (days)‡ | 50 (22, 96) | 70 (49, 125) | 42 (18, 89) | 66 (49, 85) |
Outcome at 18–24 months | ||||
Disability† | 4/23 (17%) | 7/14 (50%)*** | 3/21 (14%) | 3/10 (30%) |
Cerebral palsy† | 2/23 (9%) | 1/14 (7%) | 0/21 (0%) | 1/10 (10%) |
Results presented as mean (SD), number (percentage) or median (IQR) as appropriate.
*p<0.01; **p<0.05' ***p< 0.1.
†Four patients were excluded from analysis as follow-up data were not available.
‡Calculated only for survivors.
§Any morbidity was defined as a composite of severe retinopathy of prematurity requiring treatment, necrotising enterocolitis ≥ stage 2a, chronic lung disease, culture positive sepsis occurring after resolution of aPHT episode or intraventricular haemorrhage ≥ grade 3.
aPHT, acute pulmonary hypertension; iNO, inhaled nitric oxide.